Yüklüyor......
TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription
Comparatively less toxic and more tolerated, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are recommendable for advanced non-small-cell lung cancer (NSCLC) patients with EGFR-sensitive mutations. Some EGFR wild-type patients with specific biomarkers also show a response to...
Kaydedildi:
| Yayımlandı: | Cell Death Dis |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Publishing Group UK
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6433914/ https://ncbi.nlm.nih.gov/pubmed/30911072 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-019-1519-z |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|